

PRESS RELEASE

Hansa Biopharma to host conference call to provide interim results for January-September 2021 and Business Update

Lund, Sweden October 7, 2021 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-September 2021 at 8:00 CET on October 21, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 856 64 27 07

United Kingdom: +44 333 300 92 74

United States: +1 646 722 49 04

The webcast will be available on <https://streams.eventcdn.net/hansa/2021q3>

Updated Calendar and Events 2021/2022

Oct 21, 2021	Interim report for Jan-Sep 2021
Oct 22+26, 2021	Kempen NDRS EU/US (virtual)
Nov 10, 2021	Ökonomisk Ugebrev Life Science Conf., Copenhagen
Nov 11, 2021	Redeye Life Science Day 2021, Stockholm
Nov 16-18, 2021	Jefferies Global Healthcare Conference, London/virtual
Nov 25, 2021	Erik Penser Banks Bolagsdag, Stockholm/virtual
Dec 1-2, 2021	Geneva European MidCap event
Jan 9-13, 2021	JPM Week, San Francisco
Jan 10-13, 2021	HC Wainwright BioConnect (virtual)
Feb 3, 2022	Year-End report for Jan - Dec 2021
Mar 15, 2022	Carnegie Healthcare Seminar 2022, Stockholm

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Katja Margell, *Head of Corporate Communications*

M: +46 (0) 768-198 326

E: katja.margell@hansabiopharma.com